ST Wanbang: Subsidiary Product Xinshuai Alkaloid Injection Selected for Inter-Provincial Alliance Procurement

ST Wansheng announced that its wholly-owned subsidiary, Wanshengde Pharmaceutical, participated in a centralized volume-based procurement bidding for an inter-provincial alliance, and its product, Huperzine A injection, was selected. This procurement cycle lasts for two years and involves many participating provinces. This product is the company's core exclusive formulation, which obtained its registration certificate in 2018, and its core components have received several honors and patents in multiple countries. The company is the only manufacturer and has the integrated advantage of both active pharmaceutical ingredients and formulations. Being selected will help broaden distribution channels, expand sales, and enhance market share and brand influence; however, subsequent execution and sales are subject to policy and market impacts, leading to uncertainties regarding performance.